Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LGLigand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ Global Market · Currency in USD
$303.53 ▼ -4.29 (-1.39%)
At close: Oct 23, 4:00 PM ET. Market closed.
$303.53 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$307.82
Open
$306.11
Day's Range
$302.79 – $313.28
52 Week Range
$175.89 – $326.63
Volume
366,502
Avg. Volume
326,360
Market Cap
$6.05B
Beta (5Y Monthly)
1.01
PE Ratio (TTM)
30.32
EPS (TTM)
$9.83
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Jul 2, 2010
1y Target Est
$339.43

Profile: Ligand Pharmaceuticals Incorporated

Sector
Healthcare
Industry
Biotechnology
Full-time employees
47
CEO
Todd C. Davis
Website
ligand.com

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $2.33 · Revenue est. $77.00M
DateEst.Actual
Aug 6, 2026$2.01$2.37Beat
May 14, 2026$1.84$1.63Miss
Feb 26, 2026$1.46$2.02Beat
Nov 6, 2025$1.97$3.09Beat
Aug 7, 2025$1.42$1.60Beat
May 8, 2025$1.21$1.33Beat

Analyst view

Consensus price target
$339.43 ▲ +11.8%
Range $326.00 – $358.00
Rating: Buy
Buy 72% · Hold 22% · Sell 6%

Get free alerts on LGND and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.